⌕
UroGen Pharma · URGN · Nasdaq
Tenet 44 · Weak
Compare
$29.87+6.30%At closeTenet 44 · Weak
$29.87+1.77 (+6.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

UroGen Pharma (URGN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~23.0%/yr (FY21→FY25), net margin −139.8%. Worth your attention in FY25: Share count (+117.8%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)▲21.4%
109.8
FY21→FY25CAGR +23.0%/yr
Net income ($M)▼21.0%
−153.5
FY21→FY25CAGR —
Free cash flow ($M)▼67.7%
−162.7
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+117.8%

22.3mn → 48.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$289.0K

steady at 0.3% of revenue (−2.0% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)109.8Revenue−12.4COGS97.3Gross profit−67.1R&D−155.1SG&A−124.9Op income−28.6Tax & other−153.5Net income

-140¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 89.3% → 88.7%. Net margin -139.8% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
250,253.0109,788.090,398.082,713.064,357.048,042.0▲21.4%+23.0%
Cost of revenue
21,502.012,447.08,881.09,361.07,654.05,157.0▲40.2%+24.6%
Gross profit
228,751.097,341.081,517.073,352.056,703.042,885.0▲19.4%+22.7%
Research & development
73,211.067,107.057,145.045,614.052,906.047,642.0▲17.4%+8.9%
Selling, general & admin
186,478.0155,097.0121,154.093,274.082,838.087,535.0▲28.0%+15.4%
Total operating expenses
259,689.0222,204.0178,299.0138,888.0135,744.0135,177.0▲24.6%+13.2%
Operating incomefeeds ROC rank
−30,938.0−124,863.0−96,782.0−65,536.0−79,041.0−92,292.0▼29.0%—
Other income, net
−33,215.0−28,553.0−27,260.0−32,788.0−28,987.0−17,079.0——
Pretax income
−64,153.0−153,416.0−124,042.0−98,324.0−108,028.0−109,371.0▼23.7%—
Income tax
1,598.078.02,832.03,920.01,755.01,449.0▼97.2%−51.8%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−65,751.0−153,494.0−126,874.0−102,244.0−109,783.0−110,820.0▼21.0%—
Per share
Diluted shares (mn)
49.0548.6846.0934.1223.4422.35▲5.6%+21.5%
Margins
Gross margin87th pct in Healthcare
91.4%88.7%90.2%88.7%88.1%89.3%▼1.5pp−0.6pp
Operating margin
−12.4%−113.7%−107.1%−79.2%−122.8%−192.1%▼6.7pp+78.4pp
Net margin20th pct in Healthcare
−26.3%−139.8%−140.4%−123.6%−170.6%−230.7%▲0.5pp+90.9pp
† TTM = trailing four quarters through 2026-09-30.
FY15 – FY20 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was UroGen Pharma's revenue last fiscal year?

UroGen Pharma reported revenue of $109.8M in fiscal 2025, up 21.4% from fiscal 2024.

What was UroGen Pharma's net income?

UroGen Pharma reported net income of −$153.5M in fiscal 2025, a net margin of −139.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.